Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has launched its biosimilar product for Stelara ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...

There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, ...

Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.

MyHealthTeam, a Swoop company, the creator of one of the largest, engaged patient social networks in healthcare, has ...

Findings were announced from a phase 3 trial evaluating guselkumab subcutaneous induction therapy in patients with moderately to severely active ulcerative colitis.

Crohn’s disease can cause digestive issues However since it is an inflammatory disease the symptoms can go beyond the gut ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...